Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients

Pediatric Transplantation

Volumn 17, Issue 1, 2013, Pages 80-85

  Villeneuve, David ^a   Brothers, Adam ^a   Harvey, Eric ^a   Kemna, Mariska ^a   Law, Yuk ^a   Nemeth, Thomas ^a   Gantt, Soren ^a,b  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

children; cytomegalovirus; dose; infant; pharmacokinetics; transplant; valganciclovir

Indexed keywords

CREATININE; VALGANCICLOVIR;

AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; CHILD; CORRELATION ANALYSIS; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; HUMAN; INFANT; OBSERVATIONAL STUDY; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; PERSONALIZED MEDICINE; PRESCHOOL CHILD; RECOMMENDED DRUG DOSE; SOLID ORGAN TRANSPLANTATION;

ADMINISTRATION, ORAL; ALGORITHMS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; GANCICLOVIR; HUMANS; INFANT; ORGAN TRANSPLANTATION; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84872796258     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12030     Document Type: Article

References (18)

1. Díaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006: 82: 30-35.
2. Fishman JA, Rubin RH,. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741-1751.
3. Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007: 81: 867-872.
4. Clark BS, Chang I-F, Karpen SJ, et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004: 77: 1480.
5. Valganciclovir [package insert]. San Francisco, CA: Genentech, Inc, 2010.
6. Humar A, Snydman D,. Cytomegalovirus in solid organ transplant recipients. Am J Transplant, 2009: 9: S78-S86.
7. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007: 7: 2106-2113.
8. Boutolleau D, Deback C, Bressollette-Bodin C, et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009: 81: 174-179.
9. Launay E, Théôret Y, Litalien C, et al. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. Pediatr Infect Dis J 2011: 31: 405-407.
10. Vaudry W, Ettenger R, Jara P, Varela-Fascinetto G, Bouw MR, Ives J, Walker R,. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009: 9: 636-643.
11. Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T,. Valganciclovir in adult solid organ transplant recipients: Pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009: 48: 399-418.
12. Zhao W, Baudouin V, Zhang D, Deschênes G, Le Guellec C, Jacqz-Aigrain E,. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin Pharmacokinet 2009: 48: 321-328.
13. Pescovitz MD,. Antiviral therapies for cytomegalovirus in solid-organ transplantation. Transplantation 2007: 84: S2-S6.
14. Zhao W, Fakhoury M, Fila M, Baudouin V, Deschênes G, Jacqz-Aigrain E,. Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients. Ther Drug Monit 2009: 34: 326-330.
15. Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis 2010: 12: 195-203.
16. Cremers SCLM, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 2003: 18: 1201-1208.
17. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL,. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009: 20: 629-637.
18. Kalil AC, Freifeld AG, Lyden ER, Stoner JA,. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS ONE 2009: 4: e5512.